Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 12, 2012 - Issue 6
Submit an article Journal homepage
1,210
Views
107
CrossRef citations to date
0
Altmetric
Reviews

Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors

Giulia MesianoUniversity of Torino Medical School, Institute for Cancer Research and Treatment, Department of Oncological Sciences, Laboratory of Cell Therapy of Cancer, 10060 Candiolo (Torino), Italy+390119933503; +390119933522; [email protected]
,
Maja TodorovicUniversity of Torino Medical School, Institute for Cancer Research and Treatment, Department of Oncological Sciences, Laboratory of Cell Therapy of Cancer, 10060 Candiolo (Torino), Italy+390119933503; +390119933522; [email protected]
, MD,
Loretta GammaitoniUniversity of Torino Medical School, Institute for Cancer Research and Treatment, Department of Oncological Sciences, Laboratory of Cell Therapy of Cancer, 10060 Candiolo (Torino), Italy+390119933503; +390119933522; [email protected]
,
Valeria LeuciUniversity of Torino Medical School, Institute for Cancer Research and Treatment, Department of Oncological Sciences, Laboratory of Cell Therapy of Cancer, 10060 Candiolo (Torino), Italy+390119933503; +390119933522; [email protected]
, PhD,
Lidia Giraudo DiegoUniversity of Torino Medical School, Institute for Cancer Research and Treatment, Department of Oncological Sciences, Laboratory of Cell Therapy of Cancer, 10060 Candiolo (Torino), Italy+390119933503; +390119933522; [email protected]
,
Fabrizio Carnevale-SchiancaUniversity of Torino Medical School, Institute for Cancer Research and Treatment, Department of Oncological Sciences, Laboratory of Cell Therapy of Cancer, 10060 Candiolo (Torino), Italy+390119933503; +390119933522; [email protected]
, MD,
Franca FagioliRegina Margherita Children's Hospital, Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Pz. Polonia 94, 10126 Torino, Italy
, MD,
Wanda PiacibelloUniversity of Torino Medical School, Institute for Cancer Research and Treatment, Department of Oncological Sciences, Laboratory of Cell Therapy of Cancer, 10060 Candiolo (Torino), Italy+390119933503; +390119933522; [email protected]
, MD,
Massimo AgliettaUniversity of Torino Medical School, Institute for Cancer Research and Treatment, Department of Oncological Sciences, Laboratory of Cell Therapy of Cancer, 10060 Candiolo (Torino), Italy+390119933503; +390119933522; [email protected]
, MD &
Dario SangioloUniversity of Torino Medical School, Institute for Cancer Research and Treatment, Department of Oncological Sciences, Laboratory of Cell Therapy of Cancer, 10060 Candiolo (Torino), Italy+390119933503; +390119933522; [email protected]
, MD PhD show all
Pages 673-684 | Published online: 14 Apr 2012
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Abstract

Introduction: Cytokine-induced killer (CIK) cells are heterogeneous ex vivo-expanded T lymphocytes with mixed T-NK phenotype and endowed with a wide MHC-unrestricted antitumor activity. CIK cells can be expanded from peripheral blood mononuclear cells (PBMC) cultured with the timed addition of IFN-γ, Ab anti-CD3 and IL2. A consistent subset of mature CIK cells presents a CD3+CD56+ phenotype. The CD3+CD56+ cellular subset is the main responsible for the tumor-killing activity, mostly mediated by the interaction of NKG2D receptor with MHC-unrestricted ligands (MIC A/B; ULBPs) on tumor cells.

Areas covered: In the present work, we described the biologic characteristics of CIK cells, focusing on those aspects that may favor their clinical translation. We reviewed preclinical data and analyzed reports from clinical trials. A specific paragraph is dedicated to future research perspectives in the field.

Expert opinion: CIK cells represent a realistic new option in the field of cancer immunotherapy. Crucial issues, favoring their clinical translation, are the easy availability of large amounts of expanded CIK cells and their MHC-unrestricted tumor killing, potentially effective against many tumor types. Intriguing future perspectives and open challenges are the investigation of synergisms with other immunotherapy approaches, targeted therapies or even conventional chemotherapy.

Acknowledgements

This work was supported in part by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC) (grant 2011/2014), Associazione Italiana contro le Leucemie-linfomi e mieloma (AIL) and Associazione Donatrici Italiane Sangue Cordone Ombelicale (ADISCO, ONLUS). Grant Rete Oncologica Piemonte e Valle D'Aosta 2010. D Sangiolo is supported in part by ‘Assegno di Ricerca' funded by Regione Piemonte; V Leuci is supported in part by fellowship funded by Associazione Piemontese contro le Leucemie (APL). G Mesiano is supported in part by a fellowship funded by Associazione Donatrici Italiane Sangue Cordone Ombelicale.

Notes

This box summarizes key points contained in the article.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 960.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.